Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.42 |
| ▸ | JAK1 | P23458 | 1/20 | 0.42 |
| ▸ | JAK3 | P52333 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 3/20 | 0.38 |
| ▸ | GAA | P10253 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.36 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6512038 | 0.81 | ALDH1A1 (0.41) | MAPTALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL5251446 | 0.81 | TDP1 (0.42) | MAPTALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL18398305 | 0.79 | SMN1; SMN2 (0.39) | MAPTALDH1A1GAASMN1; SMN2TXNRD1 | |
| SCHEMBL30400975 | 0.78 | ALDH1A1 (0.42) | MAPTALDH1A1HSD17B10CYP3A4MEN1 | |
| SCHEMBL21142204 | 0.78 | ALDH1A1 (0.42) | MAPTALDH1A1HSD17B10CYP3A4MEN1 | |
| SCHEMBL843761 | 0.77 | ALDH1A1 (0.51) | MAPTALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL30197179 | 0.77 | ALDH1A1 (0.51) | MAPTALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1164206 | 0.76 | TSHR (0.40) | MAPTALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL1164208 | 0.76 | TSHR (0.40) | MAPTALDH1A1CYP1A2CYP2C9CYP2C19 | |
| SCHEMBL18957424 | 0.76 | TSHR (0.40) | MAPTALDH1A1CYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8901141-B2 | Tricyclic compounds having corticotropin-releasing factor antagonistic activity and pharmaceutical compositions containing them | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2014-12-02 | — | — | US | disclosed |
| EP-2240485-B1 | TRICYCLIC COMPOUNDS HAVING CORTICOTROPIN-RELEASING FACTOR ANTAGONISTIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TAKEDA PHARMACEUTICAL (JP) | 2014-10-15 | — | — | EP | disclosed |
| US-8785460-B2 | Tricyclic compounds and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2014-07-22 | — | — | US | disclosed |
| US-20100298287-A1 | TRICYCLIC COMPOUNDS HAVING CORTICOTROPIN-RELEASING FACTOR ANTAGONISTIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-11-25 | — | — | US | disclosed |
| US-20090186879-A1 | TRICYCLIC COMPOUNDS AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2009-07-23 | — | — | US | disclosed |
| EP-1583531-B1 | HETEROARYL-SUBSTITUTED PYRROLO[2, 3- B]PYRIDINE DERIVATIVES AS CRF RECEPTOR ANTAGONISTS | SB PHARMCO INC (US) | 2007-04-18 | — | — | EP | disclosed |
| US-20070066640-A1 | Heteroaryl-substituted pyrrolo'2,3-b1 pyridine derivatives as crf receptor antagonists | SMITHKLINE BEECHAM (CORK) LIMITED (IE) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070066640-A1 | Heteroaryl-substituted pyrrolo'2,3-b1 pyridine derivatives as crf receptor antagonists | CRHR1, CRHR2, CRH | MAPT 3698/4885ALDH1A1 2319/4885CYP1A2 492/4885 |
| US-20090186879-A1 | TRICYCLIC COMPOUNDS AND USE THEREOF | CRHR1, CRHR2, HCRTR1 | MAPT 4205/4885ALDH1A1 2741/4885CYP1A2 320/4885 |
| US-20100298287-A1 | TRICYCLIC COMPOUNDS HAVING CORTICOTROPIN-RELEASING FACTOR ANTAGONISTIC ACTIVITY AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CRH, CRHR1, CRHR2 | MAPT 4194/4885ALDH1A1 4352/4885CYP1A2 816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.